TP53 and neoplasm: We identify frequent chromothripsis and almost ubiquitous loss of heterozygosity (LOH) of TP53, with a gain of the mutant allele, which we time using clock-like mutational signatures to have occurred years before tumor diagnosis, likely in utero or early infancy.